Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse
Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu
Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu
View: Text | PDF
Research Article Oncology

Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse

  • Text
  • PDF
Abstract

Escape of prostate cancer (PCa) cells from ionizing radiation–induced (IR-induced) killing leads to disease progression and cancer relapse. The influence of sphingolipids, such as ceramide and its metabolite sphingosine 1-phosphate, on signal transduction pathways under cell stress is important to survival adaptation responses. In this study, we demonstrate that ceramide-deacylating enzyme acid ceramidase (AC) was preferentially upregulated in irradiated PCa cells. Radiation-induced AC gene transactivation by activator protein 1 (AP-1) binding on the proximal promoter was sensitive to inhibition of de novo ceramide biosynthesis, as demonstrated by promoter reporter and ChIP-qPCR analyses. Our data indicate that a protective feedback mechanism mitigates the apoptotic effect of IR-induced ceramide generation. We found that deregulation of c-Jun induced marked radiosensitization in vivo and in vitro, which was rescued by ectopic AC overexpression. AC overexpression in PCa clonogens that survived a fractionated 80-Gy IR course was associated with increased radioresistance and proliferation, suggesting a role for AC in radiotherapy failure and relapse. Immunohistochemical analysis of human PCa tissues revealed higher levels of AC after radiotherapy failure than those in therapy-naive PCa, prostatic intraepithelial neoplasia, or benign tissues. Addition of an AC inhibitor to an animal model of xenograft irradiation produced radiosensitization and prevention of relapse. These data indicate that AC is a potentially tractable target for adjuvant radiotherapy.

Authors

Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu

×

Figure 3

ASAH1 is a ceramide-sensitive target of IR-induced AP-1 binding.

Options: View larger image (or click on image) Download as PowerPoint

ASAH1 is a ceramide-sensitive target of IR-induced AP-1 binding.
 
(A) ...
(A) Transcription factor activity assay of PPC-1 cell nuclear extracts collected after irradiation (5 Gy, 24 hours) or C6-ceramide (2 μM, 12 hours), as compared with untreated control. (B) γ-Irradiated PPC-1 cells (5 Gy, 24 hours) were subjected to ChIP targeting c-Jun–bound segments of the ASAH1 promoter with the highest concentration of putative AP-1 consensus binding sequences. Schematic of ASAH1 proximal promoter is annotated with binding sequences predicted by TESS (yellow) or TFBIND (blue) analyses or both (green). The orange line denotes the length of the –496-bp luciferase reporter used in Supplemental Figure 5. Arrows denote the positions of forward and reverse ChIP primers. (C) ChIP for c-Jun, c-Fos, or JunB binding to –753/–418 ASAH1 promoter fragment. PPC-1 cells were pretreated with ceramide pathway inhibitors, FB1 (25 μM) or myriocin (0.1 μM, 4 hours), irradiated (5 Gy, 24 hours), and evaluated for c-Jun binding to the ASAH1 promoter. An intronic ASAH1 sequence with no AP-1 consensus binding site was used as a negative control (–); a –243/–3 MMP1 promoter sequence was used as a positive control (+). Mean densitometry of AP1 amplicons normalized to input controls is shown. C, nonirradiated control. These eluates were quantitated by ChIP-qPCR analysis for (D) c-Jun or (E) c-Fos binding to the ASAH1 promoter. Results are expressed as fold of expression normalized to IgG pull-down controls (n = 4). †P < 0.05, Kruskal-Wallis test, Dunn post-hoc analysis.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts